Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: A simulation study
Cancer Epidemiology Biomarkers and Prevention, Volume 15, No. 3, Year 2006
Notification
URL copied to clipboard!
Description
Purpose: We assessed the cost-effectiveness of mammography screening for women under the age of 50, from breast cancer families without proven BRCA1/BRCA2 mutations, because current criteria for screening healthy women from breast cancer families are not evidence-based. Methods: We did simulation studies with mathematical models on the cost-effectiveness of mammography screening of women under the age of 50 with breast cancer family histories. Breast cancer screening was simulated with varying screening intervals (6, 12, 18, and 24 months) and screening cohorts (starting at ages 30, 35, 40, and 45, and continuing to age 50). Incremental costs of screening were compared with those of women ages 50 to 52 years, the youngest age group currently routinely screened in the nationwide screening program of the Netherlands, to determine cost-effectiveness. Sensitivity analyses were done to explore the effects of model assumptions. The cost-effectiveness of breast cancer screening for women over the age of 50 was not debated. Results: The most effective screening interval was found to be 12 months, which, however, seems only to be cost-effective in a small group of women under the age of 50 with at least two affected relatives, including at least one affected in the first degree diagnosed under the age of 50. Significantly, early breast cancer screening never seemed to be cost-effective in women with only one affected first-degree or second-degree relative. Conclusion: Annual breast cancer screening with mammography for women under the age of 50 seems to be cost-effective in women with strong family histories of breast cancer, even when no BRCA1/BRCA2 mutation was found in affected family members. Copyright © 2006 American Association for Cancer Research.
Authors & Co-Authors
Jacobi, Catharina E.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Nagelkerke, Nico J.D.
Netherlands, Leiden
Leids Universitair Medisch Centrum
United Arab Emirates, Al Ain
United Arab Emirates University
Van Houwelingen, J. C.
Netherlands, Leiden
Leids Universitair Medisch Centrum
de Bock, Truuske G.H.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Netherlands, Groningen
Universitair Medisch Centrum Groningen
Statistics
Citations: 11
Authors: 4
Affiliations: 3
Identifiers
Doi:
10.1158/1055-9965.EPI-05-0223
ISSN:
10559965
Research Areas
Cancer
Study Design
Cross Sectional Study
Cohort Study
Participants Gender
Female